LifeStance Health Group reported a 24% increase in total revenue to $259.6 million for Q2 2023. The company's net loss was $45.5 million, driven by stock-based compensation expense. The company is raising full year revenue and Center Margin guidance, with the following outlook for 2023: expects full year revenue of $1.01 to $1.04 billion, Center Margin of $280 to $300 million, and Adjusted EBITDA of $50 to $62 million.
Total revenue increased 24% to $259.6 million.
Total clinicians reached 6,132, up 17% year-over-year.
Net loss was $45.5 million, compared to a net loss of $68.7 million in the prior year.
Adjusted EBITDA decreased 3% to $14.1 million.
LifeStance is raising full year revenue and Center Margin guidance, with the following outlook for 2023: expects full year revenue of $1.01 to $1.04 billion, Center Margin of $280 to $300 million, and Adjusted EBITDA of $50 to $62 million. For the third quarter of 2023, the Company expects total revenue of $250 to $260 million, Center Margin of $69 to $76 million, and Adjusted EBITDA of $11 to $17 million.